Form 4: Tango Therapeutics President Adam Crystal Sells Shares
Statement of Changes in Beneficial Ownership
Tango Therapeutics President of R&D Adam Crystal exercised stock options and sold 27,000 shares under a 10b5-1 plan.
Summary
- Adam Crystal, President of R&D at Tango Therapeutics, exercised options to acquire 27,000 shares of common stock at a price of $5.20 per share.
- Following the acquisition, the reporting person sold the entire 27,000 shares in two separate transactions.
- The sales were executed at weighted average prices of $21.1931 and $21.9964 per share.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan and does not necessarily reflect a change in the executive's outlook on the company.
Positives
- The executive maintains a significant remaining beneficial ownership of 115,743 shares of common stock.
- The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to liquidity rather than reactive selling.
Negatives
- The transaction represents a divestment of equity by a key member of the R&D leadership team.
Risks
- Future share price volatility could impact the value of the remaining 115,743 shares held by the executive.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for biotech executives to manage personal financial planning and diversify holdings, and is generally viewed as neutral by the market when pre-planned.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of trading on material non-public information.
- The scale of the sale relative to the executive's total holdings is consistent with typical executive compensation and liquidity management patterns in the biotechnology sector.
Stakeholder Impact
- Shareholders should note the reduction in direct ownership by the President of R&D, though the remaining stake remains substantial.
Next Steps
- Continued monitoring of insider trading activity for TNGX.
Key Dates
| Date | Description |
|---|---|
| 2024-02-27 | Initial vesting date for the stock options exercised. |
| 2025-10-27 | Adoption date of the Rule 10b5-1 trading plan. |
| 2025-11-01 | Date of acquisition of 3,121 shares via Employee Stock Purchase Plan. |
| 2026-05-01 | Date of option exercise and subsequent sale of shares. |
| 2026-05-05 | Filing date of the Form 4. |
| 2033-03-01 | Expiration date of the stock options. |
Keywords
Tango Therapeutics, TNGX, Insider Trading, Form 4, Biotech, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.